Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human mucin and with synthetic carbohydrate-carrier conjugates
US5747048A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 6, 1994 |
| Grant date | May 5, 1998 |
| Priority date | — |
| Expiry date | Dec 6, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/808
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of producing monoclonal antibodies that bind to human cancer-associated mucin-type glycoprotein antigens comprising: (1) immunizing a host with a core structure of a mucin-type glycoprotein; (2) fusing splenocytes from said immunized host with myeloma cells to form hybridoma cells; (3) culturing said hybridoma cells on selective medium; (4) selecting hybridoma cells surviving step (3) that secrete antibody that binds to said core structure of a mucin-type glycoprotein; (5) cloning said selected hybridoma cells from step (4); (6) culturing said cloned hybridoma cells; and (7) recovering said antibody. Hybridomas and monoclonal antibodies produced by the above-described method. Methods of passive and active immunization employing the monoclonal antibodies and mucin-type glycoproteins or synthetic oligosaccharide-carrier conjugates.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.